Atea Pharmaceuticals (AVIR)
NASDAQ:AVIR
US Market
Holding AVIR?
Track your performance easily

Atea Pharmaceuticals (AVIR) Ownership - Who Owns Atea Pharmaceuticals?

208 Followers

Atea Pharmaceuticals (AVIR) Ownership Overview

11.90%14.38%8.98%11.34%53.39%
11.90% Insiders
8.98% Other Institutional Investors
11.34% ETFs
53.39% Public Companies and
Individual Investors
The ownership structure of Atea Pharmaceuticals (AVIR) stock is a mix of institutional, retail, and individual investors. Approximately 34.71% of the company’s stock is owned by Institutional Investors, 11.90% is owned by Insiders, and 53.39% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Jun 21, 2024
Bruce Polsky
Director
xxxxxxxxxxxxx
$61053
Jun 07, 2024
Jean Pierre Sommadossi
President, Ceo, And Chairman,director
xxxxxxxxxxxxx
$4024

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
8,162,914Insider9.60%28,570,199
4,262,823Institution5.05%14,919,881
3,797,568Institution4.50%13,291,488
3,576,266Institution4.24%12,516,931
1,811,377Institution2.15%6,339,820
958,300Institution1.14%3,354,050
876,763Institution1.04%3,068,671
869,276Institution1.03%3,042,466
811,867Institution0.96%2,841,535
811,503Insider0.96%2,840,261

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
3,576,266Institution4.24%12,516,931
1,811,377Institution2.15%6,339,820
958,300Institution1.14%3,354,050
876,763Institution1.04%3,068,671
869,276Institution1.03%3,042,466
811,867Institution0.96%2,841,535
549,380Institution0.65%1,922,830
502,608Institution0.60%1,759,128
376,458Institution0.45%1,317,603
342,681Institution0.41%1,199,384

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
2,363,327Institution2.80%7,917,145
2,091,423Institution2.48%7,319,981
1,275,767Institution1.51%4,273,819
745,692Institution0.88%2,609,922
512,710Institution0.61%1,794,485
386,954Institution0.46%1,331,122
354,688Institution0.42%1,188,205
210,652Institution0.25%705,684
174,928Institution0.21%612,248
171,626Institution0.20%600,691

FAQ

Who Owns Atea Pharmaceuticals (AVIR)?
According to the latest TipRanks data, approximately 8.98% of the company's stock is held by institutional investors, 11.90% is held by insiders, and 53.39% is held by retail investors.
    What percentage of Atea Pharmaceuticals (AVIR) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 8.98% of Atea Pharmaceuticals (AVIR) stock is held by institutional investors.
      What percentage of Atea Pharmaceuticals (AVIR) stock is held by retail investors?
      According to the latest TipRanks data, approximately 53.39% of Atea Pharmaceuticals (AVIR) stock is held by retail investors.
        Who owns the most shares of Atea Pharmaceuticals (AVIR)?
        Jean-Pierre Sommadossi owns the most shares of Atea Pharmaceuticals (AVIR).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis